Supplementum 298: Abstracts of the joint annual meeting of the Swiss Society of Cardiology (SSC), the Swiss Society for Heart and Thoracic Vascular Surgery (SSCS), the Swiss Society of Pneumology (SSP) and the Swiss Society for Thoracic Surgery (SSTS): Basel, Switzerland, June 10-12, 2026 - Orals SSC and SSCS | Synapse
June 24, 2026Open Access
Supplementum 298: Abstracts of the joint annual meeting of the Swiss Society of Cardiology (SSC), the Swiss Society for Heart and Thoracic Vascular Surgery (SSCS), the Swiss Society of Pneumology (SSP) and the Swiss Society for Thoracic Surgery (SSTS): Basel, Switzerland, June 10-12, 2026 - Orals SSC and SSCS
Puntos clave
To present recent research findings and developments in cardiology, thoracic surgery, and pneumology at the annual meeting.
Abstract submissions from various specialists in the fields of cardiology, thoracic surgery, and pneumology.
PICO estructurado
Does mavacamten improve NYHA class and reduce LVOTG in patients with obstructive hypertrophic cardiomyopathy?
P
Población
82 consecutive patients with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten across 4 Swiss referral centers. At baseline, 47/82 patients (57%) were in NYHA class III.
I
Intervención
Mavacamten
O
Resultado
Changes in New York Heart Association (NYHA) class and left ventricular outflow tract gradients (LVOTG)surrogate